Bionano Genomics shows a prevailing Real Value of $4.69 per share. The current price of the firm is $2.37. Based on Macroaxis valuation methodology, the firm appears to be undervalued.
Similarly, What does Bionano genomics do?
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents.
Does Cathie own BNGO? Is Cathie Wood Invested in BNGO? As of the time of this writing, it does not appear that Cathie Wood or ARK are invested in Bionano Genomics. The firm’s genomics and biomedical ETF, ARKG, currently contains 52 individual holdings.
Thereof, Does the FDA approve BNGO?
The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.
What is BNGO price target?
The 4 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 7.50, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +242.47% increase from the last price of 2.19.
Is BNGO a pump and dump?
BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.
What sector is BNGO stock?
Key Data
| Label | Value |
|---|---|
| Sector | Capital Goods |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| 1 Year Target | $11.00 |
| Today’s High/Low | $2.77/$2.57 |
What sector is BNGO in?
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space.
Is BNGO in ARKG?
Ark Invest’s Chapter in the BNGO Stock Story
The fund manager has sent some public praise BNGO’s way. Ark even has a special portfolio — Ark Genomic Revolution ETF (NYSEARCA:ARKG) — for just that sort of stock material. Thus, it was only a matter of time before the stock caught on, right?
Who owns Bionano genomics?
Top 10 Owners of Bionano Genomics Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.74% | 16,609,007 |
| The Vanguard Group, Inc. | 4.86% | 14,064,639 |
| SSgA Funds Management, Inc. | 2.49% | 7,198,880 |
| Geode Capital Management LLC | 1.63% | 4,714,883 |
Why does BioNano have tremendous potential?
The Bottom Line on BNGO Stock
Saphyr allows diseases to be more effectively researched than competing products. And, it is tremendously cheaper than other genomic-mapping tools. But it could also more successfully determine patients more susceptible to severe cases of viruses. These viruses include Covid-19.
What is a BioNano chip?
Built using proprietary Nanochannel technology, Bionano Chips for the Saphyr® and Irys® systems linearize DNA, enabling high-speed, high-throughput optical genome mapping and structural variation detection for a variety of applications including human and clinical research.
Is the Saphyr system FDA approved?
While the FDA has not approved the Saphyr System for medical diagnostics in the U.S., researchers are free to use the technology and healthcare facilities outside the U.S. are experimenting with the system as well.
Will BNGO get FDA approval?
The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.
Does Ark invest in BNGO?
Does ARK Invest in BNGO: The Bottom Line. At this time, ARK does not invest in BNGO. With that said, the company does appear to have some promise in its own right. Like all speculative small-cap companies, Bionano Genomics is a risky stock to own.
Who is BNGO stock?
(BNGO) Stock Price, News, Quote & History – Yahoo Finance.
…
Performance Outlook.
| Previous Close | 2.3200 |
|---|---|
| Bid | 2.1800 x 27000 |
| Ask | 2.2300 x 29200 |
| Day’s Range | 2.1800 – 2.3200 |
| 52 Week Range | 1.6200 – 9.1200 |
Is BNGO in Russell?
(Nasdaq: BNGO) announced today that it was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on Monday, June 28, 2021, as part of the 2021 Russell indexes reconstitution.
How many shares does BNGO have?
BioNano Genomics Inc (US:BNGO) has 292 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 83,218,166 shares.
Who owns BioNano genomics?
Top 10 Owners of Bionano Genomics Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.74% | 16,609,007 |
| The Vanguard Group, Inc. | 4.86% | 14,064,639 |
| SSgA Funds Management, Inc. | 2.49% | 7,198,880 |
| Geode Capital Management LLC | 1.63% | 4,714,883 |
Should I invest in Bio Nano?
Bionano Genomics, Inc.
may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of BNGO, demonstrate its potential to underperform the market.
Why is OCGN stock down?
Ocugen’s OCGN stock declined 3.8% on Tuesday after the FDA placed a clinical hold on a phase II/III immuno-bridging and broadening clinical study on its COVID-19 vaccine, Covaxin.
Join TheMoney.co community and don’t forget to share this post !
